Sugi Predict

Sugi Predict / Compounds / SCHEMBL2734579

SCHEMBL2734579

SCHEMBL2734579

CC(C)(C)NCCC(N)=O

nearest known ligand 0.33

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 1/20 0.32
▸ ECE1 P42892 1/20 0.32
▸ POLB P06746 1/20 0.32
▸ GAA P10253 1/20 0.31
▸ MAOA P21397 1/20 0.31
▸ MAOB P27338 1/20 0.31
▸ KMT2A Q03164 2/20 0.30
▸ MEN1 O00255 1/20 0.30
▸ FAAH O00519 1/20 0.30
▸ TP53 P04637 1/20 0.30
▸ CYP1A2 P05177 1/20 0.30
▸ CYP3A4 P08684 1/20 0.30
▸ CYP2C19 P33261 1/20 0.30
▸ SOAT1 P35610 1/20 0.30
▸ TP53BP1 Q12888 2/20 0.30
▸ ALOX15 P16050 1/20 0.30
▸ BLM P54132 1/20 0.30
▸ PMP22 Q01453 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3314749 0.88 POLB (0.38) ALDH1A1ECE1POLBMAOAMAOB
SCHEMBL22851371 0.86 POLB (0.40) POLBMAOAMAOBKMT2AMEN1
SCHEMBL21787661 0.79 — —
SCHEMBL2835152 0.79 DPP4 (0.33) ALOX15
SCHEMBL14176533 0.79 POLB (0.33) POLBGAATP53BP1
SCHEMBL1347705 0.78 TDP1 (0.33) —
SCHEMBL13993954 0.77 ALDH1A1 (0.45) ALDH1A1POLBGAATP53BP1
SCHEMBL1983625 0.77 LMNA (0.40) ECE1POLB
Hydrochloric Acid SCHEMBL2653260 0.75 NAALAD2 (0.39) ECE1POLB
SCHEMBL13576193 0.75 POLB (0.32) POLBGAAKMT2ATP53BP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100137315-A1 Sphingosine Kinase Inhibitors and Methods of Their Use APOGEE BIOTECHNOLOGY CORPORATION (US) 2010-06-03 — — US claimed
EP-1928848-A2 SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE Apogee Biothechnology Corporation (US) 2008-06-11 — — EP claimed
EP-1904439-A2 SPHINGOSINE KINASE INHIBITORS Apogee Biothechnology Corporation (US) 2008-04-02 — — EP claimed
WO-2007019251-A9 SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE APOGEE BIOTECHNOLOGY CORP (US) 2007-04-19 — — WO claimed
WO-2007019251-A2 SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE APOGEE BIOTECHNOLOGY CORPORATION (US) 2007-02-15 — — WO claimed
US-20070032531-A1 SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE APOGEE BIOTECHNOLOGY CORPORATION (US) 2007-02-08 — — US claimed
WO-2006138660-A2 SPHINGOSINE KINASE INHIBITORS APOGEE BIOTECHNOLOGY CORPORATION (US) 2006-12-28 — — WO claimed
US-20060287317-A1 SPHINGOSINE KINASE INHIBITORS APOGEE BIOTECHNOLOGY CORPORATION (US) 2006-12-21 — — US claimed
US-RE49811-E1 Sphingosine kinase inhibitors APOGEE BIOTECHNOLOGY CORPORATION (US) 2024-01-23 — — US disclosed
US-11685722-B2 Inhibition of Olig2 activity Curtana Pharmaceuticals, Inc. (US) 2023-06-27 — — US disclosed
EP-3407912-B1 METHODS FOR ENHANCING THE POTENCY OF THE IMMUNE CHECKPOINT INHIBITORS INST NAT SANTE RECH MED (FR) 2022-05-18 — — EP disclosed
US-11242323-B2 Inhibition of OLIG2 activity Curtana Pharmaceuticals, Inc. (US) 2022-02-08 — — US disclosed
US-20210347785-A1 PREPARATION AND APPLICATION OF AROMATIC COMPOUND HAVING IMMUNOREGULATORY FUNCTION SHANGHAI ENNOVABIO PHARMACEUTICALS CO., LTD. (CN) 2021-11-11 — — US disclosed
US-20210253535-A1 INHIBITION OF OLIG2 ACTIVITY Curtana Pharmaceuticals, Inc. 2021-08-19 — — US disclosed
WO-2007019251-A9 SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE APOGEE BIOTECHNOLOGY CORP (US) 2007-04-19 — — WO disclosed
WO-2007019251-A2 SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE APOGEE BIOTECHNOLOGY CORPORATION (US) 2007-02-15 — — WO disclosed
US-20070032531-A1 SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE APOGEE BIOTECHNOLOGY CORPORATION (US) 2007-02-08 — — US disclosed
WO-2006138660-A2 SPHINGOSINE KINASE INHIBITORS APOGEE BIOTECHNOLOGY CORPORATION (US) 2006-12-28 — — WO disclosed
US-20060287317-A1 SPHINGOSINE KINASE INHIBITORS APOGEE BIOTECHNOLOGY CORPORATION (US) 2006-12-21 — — US disclosed
WO-2006125805-A1 THIAZOLE DERIVATIVES AND USE THEREOF LABORATOIRES SERONO S.A. (CH) 2006-11-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210253535-A1 INHIBITION OF OLIG2 ACTIVITY GLI2, ING2, GMFG ALDH1A1 1478/4885ECE1 3298/4885POLB 1413/4885
US-20060287317-A1 SPHINGOSINE KINASE INHIBITORS SPHK1, SPHK2, S1PR1 ALDH1A1 2654/4885ECE1 358/4885POLB 2648/4885
US-11685722-B2 Inhibition of Olig2 activity GLI2, ING2, GMFG ALDH1A1 1478/4885ECE1 3298/4885POLB 1413/4885
US-20070032531-A1 SPHINGOSINE KINASE INHIBITORS AND METHODS OF THEIR USE SPHK1, SPHK2, S1PR2 ALDH1A1 3196/4885ECE1 581/4885POLB 1740/4885
US-20100137315-A1 Sphingosine Kinase Inhibitors and Methods of Their Use SPHK1, SPHK2, S1PR2 ALDH1A1 3103/4885ECE1 547/4885POLB 1926/4885
US-11242323-B2 Inhibition of OLIG2 activity POU2F2, ING2, PAX2 ALDH1A1 1801/4885ECE1 2710/4885POLB 935/4885
US-20210347785-A1 PREPARATION AND APPLICATION OF AROMATIC COMPOUND HAVING IMMUNOREGULATORY FUNCTION CD274, PDCD1, PDCD1LG2 ALDH1A1 235/4885ECE1 717/4885POLB 3417/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.